Non-myeloablative allografting from human leucocyte antigen-identical sibling donors for treatment of acute myeloid leukaemia in first complete remission

British Journal of Haematology

Volumn 120, Issue 2, 2003, Pages 281-288

  Feinstein, Lyle C ^a,b   Sandmaier, Brenda M ^a,b   Hegenbart, Ute ^c   McSweeney, Peter A ^d   Maloney, David G ^a,b   Gooley, Theodore A ^a,b   Maris, Michael B ^a,b   Chauncey, Thomas R ^a,b,e   Bruno, Benedetto ^f   Appelbaum, Frederick R ^a,b   Niederwieser, Dietger W ^c   Storb, Rainer F ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF LEIPZIG   (Germany)

^d UNIVERSITY OF COLORADO   (United States)

^e VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^f UNIVERSITY OF TURIN   (Italy)

Author keywords

AML; First remission; Non myeloablative; Transplant

Indexed keywords

CYCLOSPORIN; FLUDARABINE; LEUKOCYTE ANTIGEN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER RECURRENCE; CLINICAL ARTICLE; FEMALE; FOLLOW UP; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA REMISSION; MALE; PRIORITY JOURNAL; SAFETY; SIBLING; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ACUTE DISEASE; ADULT; AGED; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, MYELOID; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; REMISSION INDUCTION; SIBLINGS; TRANSPLANTATION, HOMOLOGOUS; VIDARABINE; WHOLE-BODY IRRADIATION;

EID: 19244366554     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2003.04057.x     Document Type: Article

References (37)

1. Baudard, M., Beauchamp-Nicoud, A., Delmer, A., Rio, B., Blanc, C.M., Zittoun, R. & Marie, J.P. (1999) Has the prognosis of adult patients with acute myeloid leukemia improved over years? A single institution experience of 784 consecutive patients over a 16-year period. Leukemia, 13, 1490.
2. Cahn, J.Y., Labopin, M., Mandelli, F., Goldstone, A.H., Eberhardt, K., Reiffers, J., Ferrant, A., Franklin, I., Hervé, P., Gratwohl, A. & Gorin, N.C. (1995) Autologous bone marrow transplantation for first remission acute myeloblastic leukemia in patients older than 50 years: a retrospective analysis of the European Bone Marrow Transplant Group. Blood, 85, 575-579.
3. Cassileth, P.A., Harrington, D.P., Appelbaum, F.R., Lazarus, H.M., Rowe, J.M., Paietta, E., Willman, C., Hurd, D.D., Bennett, J.M., Blume, K.G., Head, D.R. & Wiernik, P.H. (1998) Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. New England Journal of Medicine, 339, 1649-1656.
4. De Witte, T., van Biezen, A., Hermans, J., Labopin, M., Runde, V., Or, R., Meloni, G., Mauri, S.B., Carella, A., Apperley, J., Gratwohl, A. & Laporte, J.P. (1997) Autologous bone marrow transplantation for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS. Chronic and Acute Leukemia Working Parties of the European Group for Blood and Marrow Transplantation. Blood, 90, 3853-3857.
5. Dombret, H., Chastang, C., Fenaux, P., Reiffers, J., Bordessoule, D., Bouabdallah, R., Mandelli, F., Ferrant, A., Auzanneau, G., Tilly, H., Yver, A. & Degos, L. for the AML Co-operative Study Group (1995) A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. New England Journal of Medicine, 332, 1678-1683.
6. Durnam, D.M., Anders, K.R., Fisher, L., O'Quigley, J.O., Bryant, E.M. & Thomas, E.D. (1989) Analysis of the origin of marrow cells in bone marrow transplant recipients using a Y-chromosome-specific in situ hybridization assay. Blood, 74, 2220-2226.
7. Gale, R.P., Park, R.E., Dubois, R.W., Herzig, G.P., Hocking, W.G., Horowitz, M., Keating, A., Kempin, S., Linker, C.A., Schiffer, C.A., Wiernik, P.H. & Weisdorf, K.R. (1999) Delphi-panel analysis of appropriateness of high-dose therapy and bone marrow transplants in adults with acute myelogenous leukemia in 1st remission. Leukemia Research, 23, 709-718.
8. Godwin, J.E., Kopecky, K.J., Head, D.R., Willman, C.L., Leith, C.P., Hynes, H.E., Balcerzak, S.P. & Appelbaum, F.R. (1998) A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group Study (9031). Blood, 91, 3607-3615.
9. Goldstone, A.H., Burnett, A.K., Wheatley, K., Smith, A.G., Hutchinson, R.M., Clark, R.E. & the Medical Research Council Adult Leukemia Working Party (2001) Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood, 98, 1302-1311.
10. Goodrich, J.M., Bowden, R.A., Fisher, L., Keller, C., Schoch, G. & Meyers, J.D. (1993) Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Annals of Internal Medicine, 118, 173-178.
11. Gooley, T.A., Leisenring, W., Crowley, J. & Storer, B.E. (1999) Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Statistics in Medicine, 18, 695-706.
12. Grimwade, D., Walker, H., Oliver, F., Wheatley, K., Harrison, C., Harrison, G., Rees, J., Hann, I., Stevens, R., Burnett, A. & Goldstone, A. (1998) The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood, 92, 2322-2333.
13. Grimwade, D., Walker, H., Harrison, G., Oliver, F., Chatters, S., Harrison, C., Wheatley, K., Burnett, A.K., Goldstone, A.H. & the Medical Research Council Adult Leukemia Working Party (2001) The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML); analysis of 10 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood, 98, 1312-1320.
14. Harousseau, J.-L., Cahn, J.-Y., Pignon, B., Witz, F., Milpied, N., Delain, M., Lioure, B., Lamy, T., Desablens, B., Guilhot, F., Caillot, D., Abgrall, J.-F., Francois, S., Briere, J., Guyotat, D., Casassus, P., Audhuy, B., Tellier, Z., Hurteloup, P. & Herve, P. (1997) Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. Blood, 90, 2978-2986.
15. Harris, N.L., Jaffe, E.S., Diebold, J., Flandrin, G., Muller-Hermelink, H.K., Vardiman, J., Lister, T.A. & Bloomfield, C.D. (1999) World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the clinical advisory committee meeting - Airlie House, Virginia, November 1997. Journal of Clinical Oncology, 17, 3835-3849.
16. Horowitz, M.M. & Keating, A. (2000) Report on state of the art in blood and marrow transplantation: the IBMTR/ABMTR summary slides with guide. IBMTR/ABMTR Newsletter, 7, 3-10.
17. Horowitz, M.M., Gale, R.P., Sondel, P.M., Goldman, J.M., Kersey, J., Kolb, H.-J., Rimm, A.A., Ringden, O., Rozman, C., Speck, B., Truitt, R.L., Zwaan, F.E. & Bortin, M.M. (1990) Graft-versus-leukemia reactions after bone marrow transplantation. Blood, 75, 555-562.
18. Leith, C.P., Chir, B., Kopecky, K.J., Godwin, J., McConnell, T., Sloyak, M.L., Chen, I.-M., Head, D.R., Appelbaum, F.R. & Willman, C.L. (1997) Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group Study. Blood, 89, 3323-3329.
19. McSweeney, P.A., Niederwieser, D., Shizuru, J.A., Sandmaier, B.M., Molina, A.J., Maloney, D.G., Chauncey, T.R., Gooley, T.A., Hegenbart. U., Nash, R.A., Radich, J., Wagner, J.L., Minor, S., Appelbaum, F.R., Bensinger, W.I., Bryant, E., Flowers, M.E.D., Georges, G.E., Grumet, F.C., Kiem, H.-P., Torok-Storb, B., Yu, C., Blume, K.G. & Storb, R.F. (2001) Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood, 97, 3390-3400.
20. Maris, M.B., Sandmaier, B.M., Niederwieser, D., Maloney, D.G., McSweeney, P.A., Chauncey, T., Shizuru, J., Sahebi, F., Blume, K., Forman, S. & Storb, R. (2000) The effect of donor lymphocyte infusions (DLI) on chimerism and persistent disease after non-myeloablative hematopoietic stem cell transplant (HSCT). Blood, 96, 477a.
21. Marmont, A.M., Horowitz, M.M., Gale, R.P., Sobocinski, K., Ash, R.C., van Bekkum, D.W., Champlin, R.E., Dicke, K.A., Goldman, J.M., Good, R.A., Herzig, R.H., Hong, R., Masaoka, T., Rimm, A.A., Ringden, O., Speck, B., Weiner, R.S. & Bortin, M.M. (1991) T-cell depletion of HLA-identical transplants in leukemia. Blood, 78, 2120-2130.
22. Martin, P.J., Hansen, J.A., Buckner, C.D., Sanders, J.E., Deeg, H.J., Stewart, P., Appelbaum, F.R., Clift, R., Fefer, A., Witherspoon, R.P., Kennedy, M.S., Sullivan, K.M., Flournoy, N., Storb, R. & Thomas, E.D. (1985) Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts. Blood, 66, 664-672.
23. Rowe, J.M., Andersen, J.W., Mazza, J.J., Bennett, J.M., Paietta, E., Hayes, F.A., Oette, D., Cassileth, P.A., Stadtmauer, E.A. & Wiernik, P.H. (1995) A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55-70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood, 86, 457-462.
24. Sandmaier, B.M., Maloney, D.G., Gooley, T., Hegenbart, U., Shizuru, J., Sahebi, F., Chauncey, T., Agura, E., Bruno, B., McSweeney, P., Forman, S., Blume, K., Niederwieser, D. & Storb, R. (2001) Nonmyeloablative hematopoietic stem cell transplants (HSCT) from HLA-matched related donors for patients with hematologic malignancies: clinical results of a TBI-based conditioning regimen. Blood, 98, 742a-743a.
25. Saral, R., Burns, W.H., Laskin, O.L., Santos, G.W. & Lietman, P.S. (1981) Acyclovir prophylaxis of herpes-simplex-virus infections. New England Journal of Medicine, 305, 63-67.
26. Shlomchik, W.D., Couzens, M.S., Tang, C.B., McNiff, J., Robert, M.E., Liu, J., Shlomchik, M.J. & Emerson, S.G. (1999) Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science, 285, 412-415.
27. Sievers, E.L., Larson, R.A., Stadmauer, E.A., Estey, E., Löwenberg, B., Dombret, H., Karanes, C., Theobold, M., Bennett, J.M., Sherman, M.L., Berger, M.S., Eten, C.B., Loken, M.R., van Dongen, J.J.M., Bernstein, I.D. & Appelbaum, F.R. (2001) Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. Journal of Clinical Oncology, 19, 3244-3254.
28. Slavin, M.A., Osborne, B., Adams, R., Levenstein, M.J., Schoch, H.G., Feldman, A.R., Meyers, J.D. & Bowden, R.A. (1995) Efficacy and safety of fluconazole for fungal infections after marrow transplant: a prospective, randomized, double-blind study. Journal of Infectious Diseases, 171, 1545-1552.
29. Slovak, M.L., Kopecky, K.J., Cassileth, P.A., Harrington, D.H., Theil, K.S., Mohamed, A., Paietta, E., Willman, C.L., Head, D.R., Rowe, J.M., Forman, S.J. & Appelbaum, F.R. (2000) Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood, 96, 4075-4083.
30. Stone, R.M., Berg, D.T., George, S.L., Dodge, R.K., Paciucci, P.A., Schulman, P., Lee, E.J., Moore, J.O., Powell, B.L. & Schiffer, C.A. for the Cancer and Leukemia Group B (1995) Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. New England Journal of Medicine, 332, 1671-1677.
31. Sullivan, K.M. (1999) Graft-versus-host-disease. In: Hematopoietic Cell Transplantation, 2nd edn (ed. by E.D. Thomas, K.G. Blume & S.J. Forman), pp. 515-536. Blackwell Science, Boston.
32. Sullivan, K.M., Dahlberg, S., Storb, R., Witherspoon, R., Deeg, H.J., Doney, K., Appelbaum, F.R. & Thomas, E.D. (1983) Infection prophylaxis in patients with chronic graft-vs-host disease (GVHD). Experimental Hematology, 11, 193.
33. Sullivan, K.M., Weiden, P.L., Storb, R., Witherspoon, R.P., Fefer, A., Fisher, L., Buckner, C.D., Anasetti, C., Appelbaum, F.R., Badger, C., Beatty, P., Bensinger, W., Berenson, R., Bigelow, C., Cheever, M.A., Clift, R., Deeg, H.J., Doney, K., Greenberg, P., Hansen, J.A., Hill, R., Loughran, T., Martin, P., Neiman, P., Petersen, F.B., Sanders, J., Singer, J., Stewart, P. & Thomas, E.D. (1989) Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood, 73, 1720-1728.
34. Ugozzoli, L., Yam, P., Petz, L.D., Ferrara, G.B., Champlin, R.E., Forman, S.J., Koyal, D. & Wallace, R.B. (1991) Amplification by the polymerase chain reaction of hypervariable regions of the human genome for evaluation of chimerism after bone marrow transplantation. Blood, 77, 1607-1615.
35. Weiden, P.L., Flournoy, N., Thomas, E.D., Prentice, R., Fefer, A., Buckner, C.D. & Storb, R. (1979) Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. New England Journal of Medicine, 300, 1068-1073.
36. Weiden, P.L., Sullivan, K.M., Flournoy, N., Storb, R., Thomas, E.D. & the Seattle Marrow Transplant Team (1981) Antileukemic effect of chronic graft-versus-host disease. Contribution to improved survival after allogeneic marrow transplantation. New England Journal of Medicine, 304, 1529-1533.
37. Zittoun, R.A., Mandelli, F., Willemze, R., De Witte, T., Labar, B., Resegotti, L., Leoni, F., Damasio, E., Visani, G., Papa, G., Caronia, F., Hayat, M., Stryckmans, P., Rotoli, B., Leoni, P., Peetermans, M.E., Dardenne, M., Vegna, M.L., Petti, M.C., Solbu, G. & Suciu, S. (1995) Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. New England Journal of Medicine, 332, 217-223.